23andMe to Present at Upcoming Investor Conferences

Rhea-AI Summary

23andMe Holding Co. (Nasdaq: ME) announced participation in key investor presentations at several upcoming conferences. The events include the Credit Suisse Healthcare Conference on November 9, 2022, the Evercore ISI HEALTHCONx Conference on November 29, 2022, and the Piper Sandler Healthcare Conference on November 30, 2022. Live webcasts of these presentations can be accessed via the Company's investor website. A replay will also be available shortly after each event. 23andMe continues to focus on its mission of advancing human genetics and healthcare.

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be participating in investor presentations at the following conferences:

• Credit Suisse Healthcare Conference on Wednesday, November 9, 2022
• Evercore ISI HEALTHCONx Conference on Tuesday, November 29, 2022
• Piper Sandler Healthcare Conference on Wednesday, November 30, 2022
  

Interested parties can access a live webcast of the presentations on the investors section of the Company website at investors.23andme.com under the “News & Events” menu. The latest information on this and other events, including any changes to presentation dates and times, can also be found there. A webcast replay will be available at the same location for a limited time within 24 hours after each event.

About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit investors.23andme.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe’s strategy, financial position, funding for continued operations, cash reserves, projected costs, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K.Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Except as required by law, 23andMe does not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

Investor Relations Contact: investors@23andMe.com
Media Contact: press@23andMe.com

FAQ

What conferences is 23andMe (ME) participating in November 2022?

23andMe will participate in the Credit Suisse Healthcare Conference on November 9, 2022, the Evercore ISI HEALTHCONx Conference on November 29, 2022, and the Piper Sandler Healthcare Conference on November 30, 2022.

Where can I watch the 23andMe (ME) investor presentations?

Live webcasts of the 23andMe investor presentations will be available on the Company's investor website under the 'News & Events' section.

Will there be a replay of the 23andMe (ME) presentations?

Yes, a replay of the presentations will be available for a limited time within 24 hours after each event.

What is the mission of 23andMe (ME)?

23andMe aims to help people access, understand, and benefit from the human genome through its genetics-led healthcare and therapeutics initiatives.

What should investors be cautious about in the 23andMe (ME) press release?

Investors are advised to consider the forward-looking statements that are subject to risks and uncertainties, which may cause actual results to differ from expectations.